Cost-utility analysis of long-acting cabotegravir plus rilpivirine for the treatment of HIV infection in the United Kingdom

被引：0
|
作者：
Parker, B. [1 ]
Chounta, V. [2 ]
Gait, C. [3 ]
Hayward, O. [4 ]
Hunjan, M. [3 ]
Schroeder, M. [2 ]
Jacob, I. [1 ]
Van de Velde, N. [2 ]
机构：
[1] Hlth Econ & Outcomes Res Ltd, Hlth Econ, Cardiff, Wales
[2] ViiV Healthcare, Global Hlth Outcomes, London, England
[3] GSK, Hlth Outcomes, London, England
[4] Hlth Econ & Outcomes Res Ltd, Med Writing, Cardiff, Wales
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P030
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [31] Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
    Michael G. Sension
    Laurence Brunet
    Ricky K. Hsu
    Jennifer S. Fusco
    Quateka Cochran
    Christine Uranaka
    Gayathri Sridhar
    Vani Vannappagari
    Jean Van Wyk
    Lewis McCurdy
    Michael B. Wohlfeiler
    Gregory P. Fusco
    Infectious Diseases and Therapy, 2023, 12 : 2807 - 2817
  • [32] Long-acting cabotegravir plus rilpivirine as maintenance therapy: ATLAS week-48 results
    Margolis, D. A.
    Swindells, S.
    Andrade-Villanueva, J-F
    Richmond, G. J.
    Rizzardini, G.
    Baumgarten, A.
    Masia, M. D. M.
    Latiff, G.
    Pokrovsky, V.
    Mrus, J. M.
    Huang, J. O.
    Hudson, K. J.
    Smith, K. Y.
    Williams, P.
    Spreen, W. R.
    HIV MEDICINE, 2019, 20 : 20 - 21
  • [33] Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirine
    Fernandez, Analuz
    Scevola, Sofia
    Niubo, Jordi
    Sykes, Craig
    Schauer, Amanda P.
    Piatti, Camila
    Morenilla, Sandra
    Sedo, Alicia
    Soriano, Irene
    Garcia, Benito
    Medina, Daniel
    Tiraboschi, Juan
    Saumoy, Maria
    Cottrell, Mackenzie L.
    Imaz, Arkaitz
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 3 - 4
  • [34] Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study
    Parker, Ben
    Ward, Tom
    Hayward, Olivia
    Jacob, Ian
    Arthurs, Erin
    Becker, Debbie
    Anderson, Sarah-Jane
    Chounta, Vasiliki
    Van de Velde, Nicolas
    PLOS ONE, 2021, 16 (02):
  • [35] Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation
    Wood, Brian R.
    Kassaye, Seble G.
    Gerstoft, Jan
    AIDS, 2023, 37 (04) : 689 - 691
  • [36] The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
    Phillips, Andrew N.
    Bansi-Matharu, Loveleen
    Cambiano, Valentina
    Ehrenkranz, Peter
    Serenata, Celicia
    Venter, Francois
    Pett, Sarah
    Flexner, Charles
    Jahn, Andreas
    Revill, Paul
    Garnett, Geoff P.
    LANCET GLOBAL HEALTH, 2021, 9 (05): : E620 - E627
  • [37] Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 infection switching to long-acting cabotegravir and rilpivirine
    Rubenstein, E.
    Diemer, M.
    Goldwirt, L.
    Lascoux-Combe, C.
    Lafaurie, M.
    Ponscarme, D.
    Denis, B.
    De Castro, N.
    Rami, A.
    Sellier, P. -O.
    Deville, L.
    Chaix, M. -L.
    Delaugerre, C.
    Molina, J. -M.
    HIV MEDICINE, 2023, 24 : 481 - 482
  • [38] Long-acting cabotegravir/rilpivirine as a safe antiretroviral therapy in solid organ transplanted HIV patients
    Moreno, Ana
    Del Campo, Santos
    Jesus Perez-Elias, Maria
    Luis Casado, Jose
    Garcia, Miguel
    Velez, Manuel
    Jesus Vivancos, Maria
    Moreno, Santiago
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 82 - 82
  • [39] HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program
    Masich, Anne M.
    Gomes, Denese
    Higginson, Robert T.
    Morgan, Zara
    Nixon, Daniel
    Tran, Melissa
    Winthrop, Elizabeth
    Fulco, Patricia P.
    AIDS, 2023, 37 (10) : 1641 - 1642
  • [40] CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING ANTIRETROVIRAL THERAPY ADMINISTERED EVERY 2-MONTHS IS COST EFFECTIVE FOR THE TREATMENT OF HIV-1 IN SPAIN
    Moreno Guillen, S.
    Rivero, A.
    Ventayol, P.
    Falco, V.
    Torralba, M.
    Schroeder, M.
    Neches, V.
    Vallejo-Aparicio, L. A.
    Mackenzie, I.
    Turner, M.
    Harrison, C.
    VALUE IN HEALTH, 2022, 25 (12) : S122 - S122
12345